For the quarter ending 2025-09-30, ABOS made $28,238K in revenue. -$26,365K in net income. Net profit margin of -93.37%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 21,968 | 37,125 | ||
| General and administrative | 4,545 | 4,625 | ||
| Total operating expenses | 26,513 | 41,750 | ||
| Loss from operations | -26,513 | -41,750 | ||
| Interest income | 1,639 | 2,015 | ||
| Interest expense | 1,068 | 1,046 | ||
| Change in fair value of embedded derivatives | -440 | -40 | ||
| Other income (expense), net | -69 | -129 | ||
| Total other income | 62 | 800 | ||
| Net loss | -26,451 | -40,950 | ||
| Unrealized gain on marketable securities | 86 | 8 | ||
| Comprehensive loss | -26,365 | -40,942 | ||
| Net loss per common share, basic (in dollars per share) | -0.44 | -0.68 | ||
| Net loss per common share, diluted (in dollars per share) | -0.44 | -0.68 | ||
| Weighted-average shares outstanding diluted (in shares) | 60,573,425 | 60,573,425 | ||
| Weighted-average shares outstanding, basic (in shares) | 60,573,425 | 60,573,425 | ||
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)